Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort

Breast Cancer Research

Table 3 Relative risk (OR) of breast cancer among 104 premenopausal case women with regular menstrual cycles throughout their lives and whose last cycle did not exceed 45 days, and their 225 matched controls, by tertiles of sex steroids^a

	Tertiles	Cases/Controls	Crude OR^a (95% CI)	Adjusted OR^b (95% CI)
Estradiol (pg/ml)
	1	42/75	1.00 (Reference)	1.00 (Reference)
	2	30/75	0.67 (0.38-1.18)	0.62 (0.34-1.15)
	3	32/75	0.71 (0.39-1.27)	0.69 (0.35-1.35)
	P for trend		0.21	0.25
Progesterone (ng/ml)
	1	32/75	1.00 (Reference)	1.00 (Reference)
	2	42/75	1.19 (0.69-2.06)	1.56 (0.83-2.97)
	3	30/75	0.92 (0.50-1.69)	1.16 (0.60-2.27)
	P for trend		0.81	0.75
Total testosterone (ng/ml)
	1	33/75	1.00 (Reference)	1.00 (Reference)
	2	37/80	1.03 (0.56-1.90)	1.07 (0.56-2.04)
	3	34/70	1.11 (0.58-2.14)	1.27 (0.62-2.61)
	P for trend		0.75	0.51
Free testosterone (pg/ml)
	1	20/75	1.00 (Reference)	1.00 (Reference)
	2	41/75	2.30 (1.15-4.58)	2.31 (1.12-4.76)
	3	43/75	2.20 (1.12-4.32)	2.43 (1.15-5.10)
	P for trend		0.03	0.03
SHBG (mmol/ml)
	1	41/75	1.00 (Reference)	1.00 (Reference)
	2	29/77	0.68 (0.38-1.21)	0.66 (0.36-1.21)
	3	34/73	0.86 (0.48-1.55)	0.93 (0.50-1.72)
	P for trend		0.60	0.78

^aOR and Wald 95% CI based on conditional logistic regression models (matching factors: age (±3 years) at enrollment, date of recruitment (±180 days), and laboratory batch). ^bFurther adjusted for age at recruitment, BMI, time between date of last menses before blood sampling and day of blood sampling; time between date of menses after blood sampling and date of blood sampling; circulating FSH and LH levels, and menstrual cycle length. BMI, body mass index; 95% CI, 95% confidence interval; FSH, follicle-stimulating hormone; LH, luteinizing hormone; OR, odds ratio; SHBG, sex hormone-binding globulin.

ISSN: 1465-542X